Bristol-myers Squibb Compnay

Viiv Healthcare UK (no.5) Limited

Viiv Healthcare UK Limited

Manoranjan Panda

Prasada Rao Jalagam

Alicia Regueiro-Ren

Pratik Devasthale

Satheesh Kesavan Nair

Prashantha Gunaga

Jeremy M Richter

Rajesh Onkardas Bora

Navnath Dnyanoba Yadav

Rajeev S Bhide

Susheel Jethanand Nara

Eldon Scott Priestley

Kumaravel Selvakumar

Donald J P Pinto

Wu Yang

Michael J Orwat

Leon M Smith, Ii

Peter W Glunz

Guohua Zhao

Andrew K Dilger

Lawrence R Marcin

Brett R Beno

Kumar Balashanmuga Pabbisetty

Srinivasan Thangathirupathy

Scott A Shaw

Vladimir Ladziata

Suresh Dhanusu

Fang Moore

Susan Nicole Pieniazek

Nicholas A Meanwell

Deqiang Niu

T G Murali Dhar

John V Duncia

Makonen Belema

Chunjian Liu

John A Bender

Annapurna Pendri

Natesan Murugesan

Robert J Cherney

Daniel S Gardner

Ramesh Kumar Sistla

Gan Wang

Van N Nguyen

Robert G Gentles

Ramakanth Sarabu

Bruce A Ellsworth

Jacob Swidorski

Richard A Hartz

Alan Xiangdong Wang

Zhong Yang

Boris M Seletsky

Julio Hernan Cuervo

Xiao Zhu

Indawati De Lucca

Jianxin Feng

Li Xu

David S Yoon

Selvakumar Kumaravel

Indawati DeLucca

Robert A Fridell

Mallikarjuna Rao Mettu

Alyssa H Antropow

Mallikarjun Reddy Sura

Jalathi S Nair

Arul Mozhi Subbiah Karuppiah

Guobin Miao

Zhengdong Zhu

Paul E Gormisky

Audrey Graham Ross

Ooha Morampudi

Piyush Agarwal

Krishna Mahadevu

Tirupathi Rao Alajangi

Vijaya Kumar Cm

Murugesan Natesan

Sreenivasulu Godesi

Shilpa Maheshwarappa Holehatti

Leon M Smith Ii

wherein and X-Xand R-R, along with other variables are as defined herein. The disclosure generally relates to substituted heterocyclic compounds of Formula (Ia), which are inhibitors of PAD4, method for preparing these compounds, pharmaceutical compositions comprising these compounds and use of these compounds in the treatment of a disease or a disorder associated with PAD4 enzyme activity.

Heterocyclic PAD4 inhibitors

The present disclosure relates to compounds of Formula (I), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions. (Formula (I))

Small molecule inhibitors of galectin-3

The present disclosure relates to compounds of Formula (I) or Formula (II), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.

The present disclosure relates to compounds of Formula (I) or (II), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.

Small molecule inhibitors of Galectin-3

The present disclosure relates to compounds of Formula (1), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods making and using such compounds and compositions.

Tetrahydropyran-based thiodisaccharide mimics as Galectin-3 inhibitors

Disclosed are compounds of Formula (I) or a salt thereof,wherein Ris: each W is independently NRor O; Z is a bond or CHR; and R, R, R, R, R, L, B, V, Y, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of ROMK, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating cardiovascular diseases.

Substituted nitrogen containing compounds

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to &#x3b1;v-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of &#x3b1;-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as &#x3b1;V integrin inhibitors

The present disclosure relates to compounds of formula I, which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions. 

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to &#x3b1;v-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of av-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions. 

Cyclobutane- and azetidine-containing mono and spirocyclic compounds as &#x3b1;V integrin inhibitors

Disclosed are compounds of Formula (I), or a salt thereof, wherein: X is CRor N; Y is CRor N, provided that Y is N only if X is N; Ris Formulae (A) or (B); each W is independently NRor O; Z is a bond or CHR; and R, R, R, R, L, R, R, R, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of ROMK, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating cardiovascular diseases. 

Substituted bicyclic heterocyclic compounds

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.

Spiroheptane salicylamides and related compounds as inhibitors of ROCK

Disclosed are compounds of Formula (I) or a salt thereof, wherein Ris (II) or (III); each W is independently NRor O; Z is a bond or CHR; and R, R, R, R, L, L, R, R, R, and n are define herein. Also disclosed are methods of using such compounds as inhibitors of ROMK, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating cardiovascular diseases. 

Substituted bicycle heterocyclic derivatives useful as ROMK channel inhibitors

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same. 

Spiroheptane salicylamides and related compounds as inhibitors of rock

Growing community of inventors

Bengaluru, India

Manoranjan Panda